Fang Chen1, Kenna Nagy1, Deborah Chavez2, Shelby Willis3, Ryan McBride3, Erick Giang1, Andrew Honda1, Jens Bukh4, Phillip Ordoukhanian3, Jiang Zhu5, Sharon Frey6, Robert Lanford2, Mansun Law7. 1. Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, California. 2. Southwest National Primate Research Center at Texas Biomedical Research Institute, San Antonio, Texas. 3. Next-Generation Sequencing and Microarray Research Cores, The Scripps Research Institute, La Jolla, California. 4. Copenhagen Hepatitis C Program, Department of Infectious Diseases, Copenhagen University Hospital, Hvidovre, Denmark; Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. 5. Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, California. 6. Saint Louis University Center for Vaccine Development, St Louis, Missouri. 7. Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, California. Electronic address: mlaw@scripps.edu.
Abstract
BACKGROUND & AIMS: We investigated antibody responses to hepatitis C virus (HCV) antigens E1 and E2 and the relevance of animal models for vaccine development. We compared antibody responses to vaccination with recombinant E1E2 complex in healthy volunteers, non-human primates (NHPs), and mice. METHODS: We analyzed 519 serum samples from participants in a phase 1 vaccine trial (ClinicalTrials.gov identifier NCT00500747) and compared them with serum or plasma samples from C57BL/6J mice (n = 28) and rhesus macaques (n = 4) immunized with the same HCV E1E2 antigen. Blood samples were collected at different time points and analyzed for antibody binding, neutralizing activity, and epitope specificity. Monoclonal antibodies from the immunized NHPs were isolated from single plasmablasts and memory B cells, and their immunogenetic properties were characterized. RESULTS: Antibody responses of the volunteers, NHPs, and mice to the non-neutralizing epitopes on the E1 N-terminus and E2 hypervariable region 1 did not differ significantly. Antibodies from volunteers and NHPs that neutralized heterologous strains of HCV primarily interacted with epitopes in the antigen region 3. However, the neutralizing antibodies were not produced in sufficient levels for broad neutralization of diverse HCV isolates. Broadly neutralizing antibodies similar to the human VH1-69 class antibody specific for antigen region 3 were produced in the immunized NHPs. CONCLUSIONS: In an analysis of vaccinated volunteers, NHPs, and mice, we found that recombinant E1E2 vaccine antigen induces high-antibody titers that are insufficient to neutralize diverse HCV isolates. Antibodies from volunteers and NHPs bind to the same neutralizing epitopes for virus neutralization. NHPs can therefore be used as a preclinical model to develop HCV vaccines. These findings also provide useful baseline values for development of vaccines designed to induce production of neutralizing antibodies.
BACKGROUND & AIMS: We investigated antibody responses to hepatitis C virus (HCV) antigens E1 and E2 and the relevance of animal models for vaccine development. We compared antibody responses to vaccination with recombinant E1E2 complex in healthy volunteers, non-human primates (NHPs), and mice. METHODS: We analyzed 519 serum samples from participants in a phase 1 vaccine trial (ClinicalTrials.gov identifier NCT00500747) and compared them with serum or plasma samples from C57BL/6J mice (n = 28) and rhesus macaques (n = 4) immunized with the same HCV E1E2 antigen. Blood samples were collected at different time points and analyzed for antibody binding, neutralizing activity, and epitope specificity. Monoclonal antibodies from the immunized NHPs were isolated from single plasmablasts and memory B cells, and their immunogenetic properties were characterized. RESULTS: Antibody responses of the volunteers, NHPs, and mice to the non-neutralizing epitopes on the E1 N-terminus and E2 hypervariable region 1 did not differ significantly. Antibodies from volunteers and NHPs that neutralized heterologous strains of HCV primarily interacted with epitopes in the antigen region 3. However, the neutralizing antibodies were not produced in sufficient levels for broad neutralization of diverse HCV isolates. Broadly neutralizing antibodies similar to the humanVH1-69 class antibody specific for antigen region 3 were produced in the immunized NHPs. CONCLUSIONS: In an analysis of vaccinated volunteers, NHPs, and mice, we found that recombinant E1E2 vaccine antigen induces high-antibody titers that are insufficient to neutralize diverse HCV isolates. Antibodies from volunteers and NHPs bind to the same neutralizing epitopes for virus neutralization. NHPs can therefore be used as a preclinical model to develop HCV vaccines. These findings also provide useful baseline values for development of vaccines designed to induce production of neutralizing antibodies.
Authors: Tongqing Zhou; Nicole A Doria-Rose; Cheng Cheng; Guillaume B E Stewart-Jones; Gwo-Yu Chuang; Michael Chambers; Aliaksandr Druz; Hui Geng; Krisha McKee; Young Do Kwon; Sijy O'Dell; Mallika Sastry; Stephen D Schmidt; Kai Xu; Lei Chen; Rita E Chen; Mark K Louder; Marie Pancera; Timothy G Wanninger; Baoshan Zhang; Anqi Zheng; S Katie Farney; Kathryn E Foulds; Ivelin S Georgiev; M Gordon Joyce; Thomas Lemmin; Sandeep Narpala; Reda Rawi; Cinque Soto; John-Paul Todd; Chen-Hsiang Shen; Yaroslav Tsybovsky; Yongping Yang; Peng Zhao; Barton F Haynes; Leonidas Stamatatos; Michael Tiemeyer; Lance Wells; Diana G Scorpio; Lawrence Shapiro; Adrian B McDermott; John R Mascola; Peter D Kwong Journal: Cell Rep Date: 2017-04-25 Impact factor: 9.423
Authors: Gui-Mei Li; Christopher Chiu; Jens Wrammert; Megan McCausland; Sarah F Andrews; Nai-Ying Zheng; Jane-Hwei Lee; Min Huang; Xinyan Qu; Srilatha Edupuganti; Mark Mulligan; Suman R Das; Jonathan W Yewdell; Aneesh K Mehta; Patrick C Wilson; Rafi Ahmed Journal: Proc Natl Acad Sci U S A Date: 2012-05-21 Impact factor: 11.205
Authors: Eduardo L V Silveira; Sudhir P Kasturi; Yevgeniy Kovalenkov; Ata Ur Rasheed; Patryce Yeiser; Zarpheen S Jinnah; Traci H Legere; Bali Pulendran; Francois Villinger; Jens Wrammert Journal: J Immunol Methods Date: 2014-11-08 Impact factor: 2.303
Authors: Kenneth Smith; Lori Garman; Jens Wrammert; Nai-Ying Zheng; J Donald Capra; Rafi Ahmed; Patrick C Wilson Journal: Nat Protoc Date: 2009 Impact factor: 13.491
Authors: Eduardo Salinas; Maude Boisvert; Amit A Upadhyay; Nathalie Bédard; Sydney A Nelson; Julie Bruneau; Cynthia A Derdeyn; Joseph Marcotrigiano; Matthew J Evans; Steven E Bosinger; Naglaa H Shoukry; Arash Grakoui Journal: J Clin Invest Date: 2021-01-19 Impact factor: 14.808
Authors: Johnathan D Guest; Ruixue Wang; Khadija H Elkholy; Andrezza Chagas; Kinlin L Chao; Thomas E Cleveland; Young Chang Kim; Zhen-Yong Keck; Alexander Marin; Abdul S Yunus; Roy A Mariuzza; Alexander K Andrianov; Eric A Toth; Steven K H Foung; Brian G Pierce; Thomas R Fuerst Journal: Proc Natl Acad Sci U S A Date: 2021-01-19 Impact factor: 12.779